loading
前日終値:
$3.12
開ける:
$3.13
24時間の取引高:
309.28K
Relative Volume:
2.00
時価総額:
$84.95M
収益:
$1.04M
当期純損益:
$-32.07M
株価収益率:
-0.4869
EPS:
-6.4491
ネットキャッシュフロー:
$-26.12M
1週間 パフォーマンス:
+0.96%
1か月 パフォーマンス:
+6.80%
6か月 パフォーマンス:
-29.44%
1年 パフォーマンス:
+1.95%
1日の値動き範囲:
Value
$3.08
$3.235
1週間の範囲:
Value
$3.06
$3.26
52週間の値動き範囲:
Value
$2.4501
$5.86

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
名前
Vistagen Therapeutics Inc
Name
セクター
Healthcare (1181)
Name
電話
650-577-3600
Name
住所
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
職員
41
Name
Twitter
@vistagen
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
VTGN's Discussions on Twitter

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-07-22 ダウングレード Jefferies Buy → Hold
2022-07-22 ダウングレード Robert W. Baird Outperform → Neutral
2022-07-22 ダウングレード William Blair Outperform → Mkt Perform
2021-05-20 開始されました Robert W. Baird Outperform
2021-02-18 開始されました Jefferies Buy
2021-01-04 アップグレード William Blair Mkt Perform → Outperform
2018-06-27 開始されました Maxim Group Buy
2018-02-08 繰り返されました Chardan Capital Markets Buy
2017-03-28 開始されました Maxim Group Buy
すべてを表示

Vistagen Therapeutics Inc (VTGN) 最新ニュース

pulisher
Nov 08, 2024

Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com

Nov 06, 2024
pulisher
Nov 05, 2024

Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire

Nov 05, 2024
pulisher
Nov 02, 2024

Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise

Nov 01, 2024
pulisher
Oct 31, 2024

VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com

Oct 31, 2024
pulisher
Oct 15, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha

Oct 15, 2024
pulisher
Oct 12, 2024

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN

Oct 12, 2024
pulisher
Oct 11, 2024

Mental Disorder Treatment Market Global Industry Forecast - openPR

Oct 11, 2024
pulisher
Oct 10, 2024

Vistagen, The Goldie Hawn Foundation, and MindUP students Rings the Nasdaq Stock Market Closing Bell on World Mental Health Day - Nasdaq

Oct 10, 2024
pulisher
Oct 09, 2024

Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance UK

Oct 09, 2024
pulisher
Oct 09, 2024

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - sharewise

Oct 09, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance

Sep 24, 2024
pulisher
Sep 24, 2024

Vistagen advances phase 3 trial for social anxiety treatment By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 23, 2024

Vistagen advances phase 3 trial for social anxiety treatment - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - StockTitan

Sep 23, 2024
pulisher
Sep 06, 2024

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga

Sep 06, 2024
pulisher
Sep 06, 2024

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance

Sep 06, 2024
pulisher
Sep 06, 2024

Mental Disorder Treatment Market Expected to Expand at a Steady - openPR

Sep 06, 2024
pulisher
Sep 05, 2024

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance

Sep 05, 2024
pulisher
Sep 03, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat

Sep 03, 2024
pulisher
Sep 03, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World

Sep 03, 2024
pulisher
Aug 30, 2024

Mental Disorder Treatment Market Detailed In New Research - openPR

Aug 30, 2024
pulisher
Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada

Aug 28, 2024
pulisher
Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay - Investing.com

Aug 28, 2024
pulisher
Aug 24, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49 - Defense World

Aug 24, 2024
pulisher
Aug 24, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50 Day Moving Average of $3.49 - MarketBeat

Aug 24, 2024
pulisher
Aug 21, 2024

The Globe and Mail - The Globe and Mail

Aug 21, 2024
pulisher
Aug 21, 2024

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates - MSN

Aug 21, 2024
pulisher
Aug 19, 2024

VTGN (Vistagen Therapeutics) 3-Year Revenue Growth Rate : -47.50% (As of Jun. 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 18, 2024

VTGN (Vistagen Therapeutics) Enterprise Value : $-17.63 Mil (As of Aug. 19, 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) to Post Q2 2025 Earnings of ($0.39) Per Share, William Blair Forecasts - Defense World

Aug 17, 2024
pulisher
Aug 17, 2024

VTGN (Vistagen Therapeutics) Cash-to-Debt : 54.45 (As of Jun. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

Q2 2025 EPS Estimates for Vistagen Therapeutics, Inc. Lifted by Analyst (NASDAQ:VTGN) - MarketBeat

Aug 16, 2024
pulisher
Aug 15, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Call Transcript - Insider Monkey

Aug 15, 2024
pulisher
Aug 15, 2024

Vanguard Group Inc. Sells 41,346 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Aug 15, 2024
pulisher
Aug 14, 2024

Earnings call: Vistagen advances in Phase 3 trials for SAD treatment - Investing.com Canada

Aug 14, 2024
pulisher
Aug 13, 2024

VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025 - InvestorPlace

Aug 13, 2024
pulisher
Aug 13, 2024

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update - wallstreet:online

Aug 13, 2024
pulisher
Aug 11, 2024

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World

Aug 11, 2024
pulisher
Aug 07, 2024

Vistagen Therapeutics (VTGN) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat

Aug 07, 2024

Vistagen Therapeutics Inc (VTGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.41
price up icon 1.47%
$83.38
price up icon 1.26%
$46.83
price down icon 6.86%
$410.00
price up icon 1.85%
$205.47
price down icon 0.65%
$110.64
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):